Project Grant R03TR004607
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$174K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) in the amount of $942,998.76 is funding research at Health Research, Inc. at Roswell Park in Buffalo, NY to investigate the role of psychosocial stress and its effects on the tumor microenvironment in triple negative breast cancer (TNBC). The key objectives are to: 1) examine how norepinephrine induces changes in TNBC tissues and test therapeutic measures ex vivo; 2) study immune changes in...
This Project Grant award of $781,436.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395) aims to optimize anti-N-methyl-D-aspartate receptor (NMDAR) antibodies for the treatment of triple-negative breast cancer (TNBC). The key products and services to be delivered under this 5-year award, which began on April 14, 2025, include: Establishing an orthotopic mouse model of NMDAR-positive TNBC to evaluate NMDAR-targeting antibody...
The National Cancer Institute (NCI) awarded a $118,912 Project Grant under its Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill (UNC-CH) from December 1, 2024 to June 30, 2027. The grant will fund research to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). Key objectives include: 1) determining how MHC-I loss affects tumor progression and immune cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. at Roswell Park Division to conduct research focused on determining the impact of metabolic adaptations on the immune-tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The research aims to investigate the bifunctional mechanisms of the PFKFB4 enzyme in regulating metabolic and genetic plasticity within the TNBC tumor...
This $1,372,925 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Cold Spring Harbor Laboratory (CSHL) to investigate the central mechanisms underlying disrupted glucocorticoid circadian rhythms in breast cancer. The research aims to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs in response to breast cancer, identify the underlying mechanisms, and then use approaches to...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $665,155 to The Johns Hopkins University from September 2024 through August 2029 to elucidate the mechanisms connecting chronic stress and cancer metastasis. The project aims to investigate how glucocorticoids and the sympathetic nervous system drive metastasis, as well as how metastases impact the activity of the hypothalamic-pituitary-adrenal axis in a feedforward loop. This...
This $1,301,250.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research to inhibit myeloid-derived suppressor cell (MDSC) biogenesis and thereby enhance the efficacy of immunotherapy in triple-negative breast cancer. The award recipient is Health Research, Inc., a non-profit research organization based in Buffalo, New York, which will conduct this research over a 3-year period from March 1, 2025 to February...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a platelet-mediated immune checkpoint inhibitor delivery system (P-aPDL1) to enhance treatment efficacy against triple-negative breast cancer (TNBC). The $619,764 award spanning 2025-2029 aims to: 1) Increase tumor-selective P-aPDL1 accumulation by triggering local thrombus formation, and 2) Modulate the immunosuppressive tumor microenvironment by depleting...
This federal Project Grant award of $378,444 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The overarching goal is to understand how HSF1 activity in metastatic breast cancer suppresses the recruitment of antitumor CD8+ T cells, and to evaluate the efficacy of targeting HSF1 to enhance the response of metastatic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel therapies for advanced metastatic triple-negative breast cancer (TNBC). The $622,329 award to Virginia Commonwealth University aims to modulate the growth, progression, and metastasis of TNBC by inhibiting the MDA-9 protein. Key objectives include: 1) formulating an MDA-9 inhibitor called PDZ1I for clinical use and characterizing its effects on the immune...